XM does not provide services to residents of the United States of America.
P
P

Pfizer


News

US FDA approves BridgeBio's drug for rare heart condition

UPDATE 2-US FDA approves BridgeBio's drug for rare heart condition Adds background in paragraphs 6-15 Nov 22 (Reuters) - The U.S. Food and Drug Administration has approved BridgeBio's BBIO.O drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer's PFE.N blockbuster Vyndaqel.
A
P

US FDA approves BridgeBio's drug for rare heart condition

US FDA approves BridgeBio's drug for rare heart condition Nov 22 (Reuters) - The U.S. Food and Drug Administration has approved BridgeBio's BBIO.O drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer's PFE.N blockbuster Vyndaqel. The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the hea
P

Latest Zantac trial against Boehringer Ingelheim ends with hung jury

UPDATE 1-Latest Zantac trial against Boehringer Ingelheim ends with hung jury Adds detail from verdict in paragraph 2, case and counsel information By Brendan Pierson Nov 22 (Reuters) - A trial ended with a hung jury on Thursday in a California man's lawsuit alleging Boehringer Ingelheim's discontinued heartburn drug Zantac gave him bladder cancer.
G
P
S

Latest Zantac trial against Boehringer Ingelheim ends with hung jury

Latest Zantac trial against Boehringer Ingelheim ends with hung jury By Brendan Pierson Nov 22 (Reuters) - A trial ended with a hung jury on Thursday in a California man's lawsuit alleging Boehringer Ingelheim's discontinued heartburn drug Zantac gave him bladder cancer. The jury in California state court was evenly divided on whether to hold Boehringer Ingelheim liable, according to lawyers for plaintiff John Russell.
G
P
S

Viatris fined in Morocco over merger notification, sources say

UPDATE 2-Viatris fined in Morocco over merger notification, sources say Adds OCP comment in last paragraph By Ahmed Eljechtimi RABAT, Nov 21 (Reuters) - U.S. pharmaceutical giant Viatris Inc VTRS.O has been fined 7.58 million dirhams ($760,000) by Morocco's competition regulator for failing to notify it regarding its merger, two official sources said on Thursday.
P

Viatris fined in Morocco over merger notification, sources say

UPDATE 1-Viatris fined in Morocco over merger notification, sources say Adds other investigations in paragraphs 6-7 By Ahmed Eljechtimi RABAT, Nov 21 (Reuters) - U.S. pharmaceutical giant Viatris Inc . VTRS.O has been fined 7.58 million dirhams ($760,000) by Morocco's competition regulator for failing to notify it regarding its merger, two official sources said on Thursday.
P

Viatris fined in Morocco over merger notification, sources say

CORRECTED-Viatris fined in Morocco over merger notification, sources say Corrects company name in headline By Ahmed Eljechtimi RABAT, Nov 21 (Reuters) - U.S. pharmaceutical giant Viatris Inc VTRS.O has been fined 7.58 million dirhams ($760,000) by Morocco's competition regulator for failing to notify it regarding its merger, two official sources said on Thursday.
P

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO®

BRIEF-Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® Nov 21 (Reuters) - Zai Lab Ltd 9688.HK : ZAI LAB AND PFIZER ANNOUNCE STRATEGIC COLLABORATION ON THE NOVEL ANTIBACTERIAL DRUG XACDURO® (SULBACTAM-DURLOBACTAM) Source text: ID:nBw4VNw0Za Further company coverage: 9688.HK
P

US CDC expects COVID and RSV levels to increase in coming weeks

UPDATE 2-US CDC expects COVID and RSV levels to increase in coming weeks Adds background on vaccines in paragraphs 4,5 and vaccination details in paragraph 6 Nov 20 (Reuters) - The U.S. Centers for Disease Control and Prevention said on Wednesday it expects to see an increase in levels of COVID-19 and respiratory syncytial virus (RSV) in the country in the coming weeks, as they usually do during the holiday season.
P

Pfizer Announces New Chief Scientific Officer And President, Research & Development

BRIEF-Pfizer Announces New Chief Scientific Officer And President, Research & Development Nov 20 (Reuters) - Pfizer Inc PFE.N : PFIZER ANNOUNCES NEW CHIEF SCIENTIFIC OFFICER AND PRESIDENT, RESEARCH & DEVELOPMENT PFIZER INC - APPOINTS CHRIS BOSHOFF AS CHIEF SCIENTIFIC OFFICER Source text: ID:nBw2XPCfDa Further company coverage: PFE.N
P

Flagship Pioneering Announces Two New Agreements With Ampersand Biomedicines And Montai Therapeutics Under Its Strategic Partnership With Pfizer

BRIEF-Flagship Pioneering Announces Two New Agreements With Ampersand Biomedicines And Montai Therapeutics Under Its Strategic Partnership With Pfizer Nov 20 (Reuters) - FLAGSHIP PIONEERING ANNOUNCES TWO NEW AGREEMENTS WITH AMPERSAND BIOMEDICINES AND MONTAI THERAPEUTICS UNDER ITS STRATEGIC PARTNERSHIP WITH PFIZER FLAGSHIP PIONEERING: AGREEMENTS TO
P

Pfizer names oncology head Chris Boshoff as R&D chief

UPDATE 4-Pfizer names oncology head Chris Boshoff as R&D chief Adds analyst comment in paragraphs 6-7, background in paragraph 5, 9, 10,13 and 15 By Sriparna Roy and Michael Erman Nov 20 (Reuters) - Pfizer PFE.N said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development, as the drugmaker faces pressure from investors to produce profitable new drugs.
P

Pfizer names Chris Boshoff as new R&D chief, WSJ reports

Pfizer names Chris Boshoff as new R&D chief, WSJ reports Nov 20 (Reuters) - Pfizer PFE.N has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, as its R&D chief, WSJ reported on Wednesday. Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli
P

Pfizer Names Chris Boshoff As New Research And Development Chief - WSJ

BRIEF-Pfizer Names Chris Boshoff As New Research And Development Chief - WSJ Nov 20 (Reuters) - PFIZER NAMES CHRIS BOSHOFF AS NEW RESEARCH AND DEVELOPMENT CHIEF - WSJ Source text: https://tinyurl.com/226t6njn Further company coverage: PFE.N
P

European Commission Approves Pfizer’s HYMPAVZI™

BRIEF-European Commission Approves Pfizer’s HYMPAVZI™ Nov 20 (Reuters) - Pfizer Inc PFE.N : EUROPEAN COMMISSION APPROVES PFIZER’S HYMPAVZI™ (MARSTACIMAB) FOR THE TREATMENT OF ADULTS AND ADOLESCENTS WITH SEVERE HEMOPHILIA A OR B WITHOUT INHIBITORS Source text: ID:nBw1hKMN9a Further company coverage: PFE.N
P

Pfizer cannot recoup $75 million from SEC insider trading settlement, judge rules

UPDATE 1-Pfizer cannot recoup $75 million from SEC insider trading settlement, judge rules Adds details from decision, background, case citation, byline By Jonathan Stempel NEW YORK, Nov 19 (Reuters) - A federal judge on Tuesday rejected Pfizer's PFE.N bid to recoup about $75.2 million left over from a U.S. Securities and Exchange Commission insider trading settlement with billionaire Steven A.
P

Pfizer loses bid to recoup $75 million left over from SEC settlement

Pfizer loses bid to recoup $75 million left over from SEC settlement NEW YORK, Nov 19 (Reuters) - A federal judge on Tuesday rejected Pfizer's PFE.N bid to recoup about $75.2 million left over from a U.S. Securities and Exchange Commission settlement with billionaire Steven A. Cohen's hedge fund SAC Capital in an insider trading case. U.S. District Judge Victor Marrero in Manhattan said Wyeth, a drugmaker that Pfizer bought in 2009, was not a victim of the securities violations underlying the SE
P

Merck says Keytruda injection on par with approved IV version in trial

UPDATE 1-Merck says Keytruda injection on par with approved IV version in trial Adds shares in paragraph 2, background in paragraphs 7-10 Nov 19 (Reuters) - Merck MRK.N said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its treatment, likely making it even more accessible and easier to administer.
P

Arvinas Inc - 8-K SEC Filing

BRIEF-Arvinas Inc - 8-K SEC Filing Nov 19 (Reuters) - Arvinas Inc ARVN.O : ARVINAS INC - VERITAC-2 TRIAL COMPLETION DATE MOVED TO JANUARY 2025 ARVINAS INC: TOP-LINE DATA FROM VERITAC-2 PHASE 3 SECOND-LINE CLINICAL TRIAL ANTICIPATED IN THE FIRST QUARTER OF 2025 Further company coverage: ARVN.O
P

Headwinds hit Trump-fueled rally in US stocks

ANALYSIS-Headwinds hit Trump-fueled rally in US stocks Post-election rally in stocks is fading Rising yields challenge stock market stability Policy uncertainty affects pharmaceutical and defense stocks Optimism persists due to strong earnings and growth By Lewis Krauskopf NEW YORK, Nov 18 (Reuters) - A U.S. stock rally fueled by Donald Trump’s election victory is stumbling, as investors contend with everything from renewed inflation worries to uncertainty over the impact of the president-elec
C
P
T
U
L
B



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.